Keywords
Aspirin
Clopidogrel
How to Cite
Abstract
Platelet count in peripheral blood of healthy subjects with antiplatelet drugs. 20 subjects were analized. They were distributed in two groups: subject A: 10 who received aspirin (100 mg) and B:10 with Clopidogrel (75 mg) for 7 days. In all subjects studied platelet count in peripheral blood and PRP. It found a platelet count before treatment with antiplatelet agents in peripheral blood of 258,6 ± 54,46 x 109 l and 7 days after 254 ± 41,86 x 109 l (aspirin) and 285,4 ± 70, 196,5 ± 37,90 x 109 l (Clopidogrel) respectively. In the PRP of subjects before receiving aspirin was 486,5 ± 129,54 x 109 l and after 449,2 ± 85,51 x 109 l; prior to Clopidogrel ingestion was 565,2 ± 150,41 and 592,9 ± 203,46 x 109 l after treatment. Significant differences were found only for the platelet count in the Clopidogrel Group (p < 0.05). A significant decrease in platelet count was observed in peripheral blood after administration of Clopidogrel, possibly as a result of its pharmacological mechanism. More studies are needed to assess a greater number of individuals and better measure the effect of antiplatelet agents.References
Bizzozero J. On a new blood particle and its role in thrombosis and blood coagulation. Virchows Arch B Cell Pathol Incl Mol Pathol. 1982; 90: 261.
Im MJ, Kim YS, Edwards RJ, Hoopes JE, Fenselau A. The effect of bovine basic fibroblast growth factor on skin flap survival in rats. Ann Plast Surg 1992; 28 (3): 242-245.
Adler SC, Kent KJ. Enhancing wound healing with growth factors. Facial Plast Surg Clin North Am. 2002; 10 (2): 129-46.
González-Lagunas J. Plasma rico en plaquetas Rev Esp Cir Oral Maxilofac 2006; 28 (2): 89-99.
Sánchez AR, Sheridan PJ, Kupp LI. Is platelet-rich plasma the perfect enhancement factor? A current review. Int J Oral Maxillofac Implants 2003; 18(1): 93-103
Hayasaka M, Takahashi Y, Nishida Y, Yoshida Y, Hidaka S, Asai S. Comparative effect of clopidogrel plus aspirin and aspirin monotherapy on hematological parameters using propensity score matching. Vasc Health Risk Manag 2013; 9: 65-70.
González M, Arteaga-Vizcaíno M, Ruiz A, Daniela E, González B, Galué R, et al. Acción de los antiagregantes plaquetarios sobre el recuento de plaquetas en el plasma rico en plaquetas. ACHO. 2013; 2 (2): 15-22.
Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Grupo de trabajo sobre el uso de agentes antiplaquetarios en pacientes con enfermedad cardiovascular aterosclerótica de la Sociedad Europea de Cardiología. Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios. Rev Esp Cardiol. 2004; 57(10): 963-80.
Ruland S. Safety of Clopidogrel and Aspirin for stroke Prevention: Implications of the CHARISMA Trial. Drug Saf. 2008; 31(6):449-458.
Tanasescu S, Lévesque H, Thuillez C. Farmacología de la Aspirina. Rev Med Int 2000; 21; 1: 18s-26s.
Hilman R, Kenneth A, Henry M. Hematología en la práctica clínica. 4ª edic. Editorial Manual Moderno; 2005.
CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348(9038):1329–1339.
Sharis PJ, Loscalzo J. Thienopyridines: ticlopidine and clopidogrel. In: Sasahara A, Loscalzo J, editors. New Therapeutic Agents in Thrombosis and Thrombolysis, 2nd ed. New York, NY: Informa Healthcare; 2003.
Hernández Sampieri R, Fernández Collado C, Baptista LP. Metodología de la Investigación. Cuarta Edición México D.F; Editorial Mc Graw Hill. 2006.
Arias Fidias G. El Proyecto de Investigación, Introducción a la Metodología Científica Quinta Edición. Caracas-Venezuela; Editorial Episteme; 2006.
Symansky, MR., Fox, HA. Umbilical vessel catheterization: Indications, management, and evaluation of the thecnique. J Pediatr. 1972; 80(5): 820-826.
Anitua E. La utilización de los factores de crecimiento plasmáticos en cirugía oral, maxilofacial y periodoncia (PRGF). RCO 2001; 6: 305-15.
Born GVR, Cross MJ. The aggregation of the blood platelets. J Phisiol 1963; 168(1): 178-183.
Bick RL. Platelet function defects. In: Bick RL, editor. Disorders of thrombosis and hemostasis: clinical and laboratory practice. USA: Lippincott Williams & Wilkins; 2002. p. 59-90.
Magdalena F. Análisis Estadístico. Primera Edición Madrid. Editorial Osborne MacGrawHill. 2001.
Pardo A, San Martin R. Análisis de Datos en Ciencias Sociales y de Salud II. 2da edición. Madrid; Editorial Síntesis. Madrid. 2010.
Declaración de Helsinki de la AMM - Principios éticos para las investigaciones médicas en seres humanos (Internet). (Citado 18 Jun 2014). Disponible en: http://www.wma.net/es/30publications/10policies/b3/.
CIOMS working group on the revision on 2002 CIOMS Ethical guidelines for Biomedical research (Internet). (Citado 29 Oct 2015). Disponible en: http://www.cioms.ch/index.php/2012-06-10-08-47-53/ethics/cioms-guidelines-working-group.
Weibrich W, Kleis W, Hafner G. Growth factor levels in the platelet-rich plasma produced by 2 different methods: Curasan-type PRP kit versus PCCS PRP system. Int J Or Maxill Im 2002; 17(2): 184-190.
Agren MS, Rasmussen K, Pakkenberg B, Jorgensen B. Growth factor and proteinase profile Vivostat® platelet-rich fibrin linked to tissue repair. Vox Sang 2014; 107(1): 37-43.
Fontana P, Nolli S, Reber G De Moerlosse P. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Throm Haemost 2006; 4(4): 813-819.
González M, Arteaga-Vizcaíno M, Ruiz A, Briceño O, Quintero M, Atencio R, et al. Niveles del factor de crecimiento derivado de plaquetas en el plasma rico en plaquetas antes y después de antiagregantes plaquetarios Avan Biomed 2013; (2): 19-23.